REFERENCES
- Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol 2002; 5: 379–385.
- Cirasino L, Pisati A, Fasani P. Contact dermatitis from propolis. Contact Dermatitis 1997; 16: 110–11.
- Monti M, Berti F, Carminati G, Cusini M. Occupational and cosmetic dermatitis from propolis. Contact Dermatitis 1983; 9: 163.
- Bankova V, Christov R, Soev G, Popov S. Determination of phenolics from propolis by capillary gas chromatography. J Chromatogr 1992; 607: 150–153.
- Palos E, Popescu F. Apiotherapeutic products for otorhinolaryngologic diseases. Rev Chir Oncol Radiol ORL Oftalmol Stomatol Ser Oftalmol 1984; 29 (1): 53–4.
- Scheller S, Ilewicz L, Luciak M, Skrobidurska D, Stojko A, Matuga W. Biological properties and clinical application of propolis. IX. Experimental observation on the influence of ethanol extract of propolis (EEP) on dental pulp regeneration. Arzneimittelforschung 1978; 28 (2): 289–91.
- Gorbatenko AG. Treatment of ulcer patients with a 30 percent alcohol solution of propolis. Vrach Delo 1971; 3: 22–4.
- Zawadzki J, Suchy H, Scheller S. Use of propolis for treatment of vaginitis and cervicitis. Przegl Lek 1973; 30 (7): 620–3.
- Holderna E, Kedzia B. Investigation upon the combined action of propolis and antimycotic drugs on Candida albi-cans. Herba Pol 1987; 33: 145–151.
- Bankova V, Christov R, Kujumgiev A, Marcucci MC, Popov S. Chemical composition and antibacterial activity of Brazilian propolis. Z Naturforsch 1995; 50c: 167-172.
- National Committee for Clinical Laboratory Standards. Reference Method for Broth Antifungal Susceptibility Testing of Yeasts: Approved Standard. Document M 27-A. Villanova, PA: National Commettee for Clinical Laboratory Standards, 1997.
- D'Auria FD, Laino L, Strippoli V, Tecca M, Salvatore G, Battinelli L, Mazzanti G. In vitro activity of tea tree oil against Candida albicans conversion and other pathogenic fungi. J Chemother 2001; 13 (4): 377–383.
- Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 1982; 20: 7–14.
- Samaranyake LP, Raeside JM, MacFarlane TW. Factors affecting the phospholipase activity of Candida species in vitro. Sabouraudia 1984; 22: 201–207.
- Strippoli V, D'Auria FD, Simonetti N. Investigation of the activity by contact of miconazole sulfosalicylate. J Chemother 1990; 2: 371–376.
- Hazen KC, Hazen BW. Hydrophobic surface protein masking by the opportunistic fungal pathogen Candida albi-cans. Infect Immun 1992; 60 (4): 1499–1508.
- McCourtie J, Douglas II. Relationship between cell surface composition of Candida albicans and adherence to acrylic after growth on different carbon sources. Infect Immun 1981; 32: 1234–1241.
- Kimura LH, Pearsall NN. Adherence of Candida albi-cans to human buccal epithelial cells. Infect Immun 1978; 21: 64–68.
- Douglas II, Houston JG, McCourtie J. Adherence of Candida albicans to human buccal epithelial cells after growth on different carbon sources. FEMS Microbiol Lett 1981; 12: 241–43.
- Ghisalberti EL. Propolis: a review. Bee World 1979; 60: 59–84.
- Matsushige K, Kusumoto IT, Yamamoto Y, Kadota S, Namba T. Quality evaluation of propolis. 1. A comparative study on radical scavenging effects of propolis and vespae nidus. J Trad Med 1995; 12: 45–53.
- Ikeno K, Ikeno T, Miyazawa C. Effect of propolis on dental caries in rats. Caries Res 1991; 25: 347–351.
- Havsteen B. Flavonoids, a class of natural products of high pharmacological potency Biochem Pharmacol 1983; 32: 1141-1148.
- Ota C, Unterkircher C, Fantinato V, Shimizu MT. Antifungal activity of propolis on different species of Candida. Mycoses 2001; 44(9-10): 375–8.
- Kujumgiev A, Tsvetkova I, Serkedyieva Y, Bankova V, Christov R, Popov S. Antibacterial antifungal and antiviral activity of propolis of different geographic origin. J Ethnopharmacol 1999; 64 (3): 235–240.
- Calderone RA, Fonzi WA. Virulence factors in Candida albicans. TRENDS Microbiol 2001; 9: 327–335.
- Ibrahim AS, Mirbod F, Filler SG, Banno Y, Cole CT, Kitajima Y, et al. Evidence implicating phospholipase as a vir-ulence factor of Candida albicans. Infect Immun 1995; 63: 1993–98.
- Leidich SD, Ibrahim AS, Fu Y, Kou A, Jessup C, et al. Cloning and disruption of caPLB1 a phospholipase B gene involved in the pathogenicity of Candida albicans. J Biol Chem 1998; 273 (40): 26078–86.
- Pugh D, Cawson RA. The cytochemical localization of phospholipase in Candida albicans infecting the chick chorio-allantoic membrane. Sabouraudia 1997; 15: 29–35.